NASDAQ:PBYI Puma Biotechnology Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.85 +0.07 (+2.52%) (As of 06/29/2022 05:49 PM ET) Add Compare Share Today's Range$2.70▼$2.8750-Day Range$1.64▼$3.0552-Week Range$1.60▼$9.48Volume383,096 shsAverage Volume522,215 shsMarket Capitalization$128.17 millionP/E RatioN/ADividend YieldN/APrice Target$9.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PBYI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address PBYI Stock Forecast (MarketRank)Overall MarketRank™2.52 out of 5 starsMedical Sector121st out of 1,432 stocksPharmaceutical Preparations Industry44th out of 685 stocksAnalyst Opinion: 3.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 - 3.0 Analyst's Opinion Consensus RatingPuma Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.25, Puma Biotechnology has a forecasted upside of 224.6% from its current price of $2.85.Amount of Analyst CoveragePuma Biotechnology has received no research coverage in the past 90 days. Previous Next 4.4 Community Rank Outperform VotesPuma Biotechnology has received 510 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPuma Biotechnology has received 260 “underperform” votes. (Add your “underperform” vote.)Community SentimentPuma Biotechnology has received 66.23% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote “Outperform” if you believe PBYI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PBYI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPuma Biotechnology does not currently pay a dividend.Dividend GrowthPuma Biotechnology does not have a long track record of dividend growth. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Puma Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $83,658.00 in company stock.Percentage Held by Insiders19.50% of the stock of Puma Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.78% of the stock of Puma Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Puma Biotechnology are expected to grow by 650.00% in the coming year, from $0.04 to $0.30 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Puma Biotechnology is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Puma Biotechnology is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Puma Biotechnology (NASDAQ:PBYI)Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.Read More PBYI Stock News HeadlinesJune 22, 2022 | americanbankingnews.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Director Troy Edward Wilson Sells 27,858 Shares of StockJune 14, 2022 | americanbankingnews.comPuma Biotechnology (NASDAQ:PBYI) Shares Cross Above 200-Day Moving Average of $2.62June 6, 2022 | finance.yahoo.comPuma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual MeetingJune 4, 2022 | finance.yahoo.comIs Puma Biotechnology, Inc. (NASDAQ:PBYI) Popular Amongst Insiders?June 4, 2022 | finance.yahoo.comPuma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT ‘Basket’ Trial of Neratinib at the ASCO 2022 Annual MeetingMay 6, 2022 | finance.yahoo.comPuma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Fall Y/YMay 6, 2022 | finance.yahoo.comPuma Biotech (PBYI) Reports Q1 Loss, Misses Revenue EstimatesMay 4, 2022 | seekingalpha.comPuma Biotechnology Q1 2022 Earnings PreviewMay 4, 2022 | finance.yahoo.comVoyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue EstimatesApril 28, 2022 | finance.yahoo.comPuma Biotech (PBYI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?March 7, 2022 | finance.yahoo.comPuma Biotechnology to Participate in Breast Cancer Panel at Cowen’s Annual Health Care ConferenceMarch 5, 2022 | finance.yahoo.comMarket Sentiment Around Loss-Making Puma Biotechnology, Inc. (NASDAQ:PBYI)March 4, 2022 | nasdaq.comPuma Biotech (PBYI) Q4 Earnings Beat Mark, Revenues Rise Y/YSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PBYI CUSIPN/A CIK1401667 Webwww.pumabiotechnology.com Phone(424) 248-6500Fax424-248-6501Employees196Year FoundedN/ACompany Calendar Last Earnings5/05/2022Today6/29/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$9.25 High Stock Price Forecast$12.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+224.6%Consensus RatingHold Rating Score (0-4)2 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.200010) Trailing P/E RatioN/A Forward P/E Ratio71.25 P/E GrowthN/ANet Income$-29.13 million Net Margins-24.42% Pretax Margin-24.28% Return on Equity-843.16% Return on Assets-21.45% Debt Debt-to-Equity Ratio13.63 Current Ratio1.57 Quick Ratio1.47 Sales & Book Value Annual Sales$253.20 million Price / Sales0.51 Cash FlowN/A Price / Cash FlowN/A Book Value($0.06) per share Price / Book-47.50Miscellaneous Outstanding Shares44,973,000Free Float36,203,000Market Cap$128.17 million OptionableOptionable Beta1.06 Puma Biotechnology Frequently Asked Questions Should I buy or sell Puma Biotechnology stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Puma Biotechnology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PBYI, but not buy additional shares or sell existing shares. View analyst ratings for Puma Biotechnology or view top-rated stocks. What is Puma Biotechnology's stock price forecast for 2022? 3 analysts have issued 12-month target prices for Puma Biotechnology's stock. Their PBYI stock forecasts range from $6.00 to $12.00. On average, they anticipate Puma Biotechnology's share price to reach $9.25 in the next twelve months. This suggests a possible upside of 224.6% from the stock's current price. View analysts' price targets for Puma Biotechnology or view top-rated stocks among Wall Street analysts. How has Puma Biotechnology's stock performed in 2022? Puma Biotechnology's stock was trading at $3.04 on January 1st, 2022. Since then, PBYI stock has decreased by 6.3% and is now trading at $2.85. View the best growth stocks for 2022 here. When is Puma Biotechnology's next earnings date? Puma Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Puma Biotechnology. How were Puma Biotechnology's earnings last quarter? Puma Biotechnology, Inc. (NASDAQ:PBYI) posted its quarterly earnings data on Thursday, May, 5th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.05. The biopharmaceutical company had revenue of $45.70 million for the quarter, compared to the consensus estimate of $45.07 million. Puma Biotechnology had a negative trailing twelve-month return on equity of 843.16% and a negative net margin of 24.42%. The firm's quarterly revenue was down 53.5% on a year-over-year basis. During the same period last year, the company earned $0.40 earnings per share. View Puma Biotechnology's earnings history. Who are Puma Biotechnology's key executives? Puma Biotechnology's management team includes the following people: Mr. Alan H. Auerbach, Founder, Chairman, Pres, CEO & Sec. (Age 52, Pay $1.11M) (LinkedIn Profile)Mr. Maximo F. Nougues, CFO & Principal Accounting Officer (Age 53, Pay $627.85k) (LinkedIn Profile)Dr. Alvin F. Wong Pharm.d., Chief Scientific OfficerMr. Douglas Hunt B.Sc., FRAPS, Sr. VP of Regulatory Affairs, Medical Writing & Project Management (Age 57, Pay $509.04k)Mr. Jeffrey Jerome Ludwig, Chief Commercial Officer (Age 56, Pay $735.01k)Mr. Mariann Ohanesian, Sr. Director of Investor Relations Who are some of Puma Biotechnology's key competitors? Some companies that are related to Puma Biotechnology include Bicycle Therapeutics (BCYC), Altimmune (ALT), 2seventy bio (TSVT), Pharming Group (PHAR), Radius Health (RDUS), ANI Pharmaceuticals (ANIP), Kezar Life Sciences (KZR), Rani Therapeutics (RANI), Janux Therapeutics (JANX), Centessa Pharmaceuticals (CNTA), Calliditas Therapeutics AB (publ) (CALT), Amryt Pharma (AMYT), COMPASS Pathways (CMPS), Mersana Therapeutics (MRSN) and Imago BioSciences (IMGO). View all of PBYI's competitors. What other stocks do shareholders of Puma Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and (CELG). What is Puma Biotechnology's stock symbol? Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI." How do I buy shares of Puma Biotechnology? Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Puma Biotechnology's stock price today? One share of PBYI stock can currently be purchased for approximately $2.85. How much money does Puma Biotechnology make? Puma Biotechnology (NASDAQ:PBYI) has a market capitalization of $128.17 million and generates $253.20 million in revenue each year. The biopharmaceutical company earns $-29.13 million in net income (profit) each year or ($1.200010) on an earnings per share basis. How many employees does Puma Biotechnology have? Puma Biotechnology employs 196 workers across the globe. How can I contact Puma Biotechnology? Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The official website for Puma Biotechnology is www.pumabiotechnology.com. The biopharmaceutical company can be reached via phone at (424) 248-6500, via email at [email protected], or via fax at 424-248-6501. This page (NASDAQ:PBYI) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here